• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALYDIA HEALTH JADA SYSTEM; INTRAUTERINE VACUUM CONTRACTION SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALYDIA HEALTH JADA SYSTEM; INTRAUTERINE VACUUM CONTRACTION SYSTEM Back to Search Results
Model Number JADA - 1001
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)
Event Date 12/29/2021
Event Type  Injury  
Manufacturer Narrative
Based on the overall information currently available for this report, a possible contributing or causal role of the jada system for the need of escalating intervention (uterine artery embolization) to preclude permanent body damage/impairment cannot be excluded.Per the jada system ifu, "signs of patient deterioration or failure to improve indicate the need for reassessment and possibly more aggressive treatment and management of postpartum hemorrhage (pph)/abnormal postpartum uterine bleeding.", "evaluate for lacerations, retained products of conception, or other causes of bleeding prior to using jada." and "jada is not a substitute for surgical management and fluid resuscitation of life-threatening pph/abnormal postpartum uterine bleeding." out of an abundance of caution, the company will report this case as a serious injury mdr.
 
Event Description
In response to the question on the ruby study case report form (crf) about whether jada controlled abnormal postpartum uterine bleeding or hemorrhage, the answer was checked "no." following jada placement and removal the patient was treated with uterine artery embolization (uae).The subject of this report is a (b)(6) woman, race reported as white, g3p2 with no prior history of postpartum hemorrhage (pph) and no significant medical history reported.On (b)(6) 2021, she presented for an augmented vaginal delivery at 39.1 weeks.On admission, her height was noted as (b)(6), and hemoglobin (hgb) 9.1 g/dl.Her hgb at discharge was noted at 6.4 g/dl.On (b)(6) 2021, she had a c-section and received oxytocin after delivery of the placenta for ten hours.She received epidural anesthesia for delivery of an infant that weighed 3430 g.The subject was noted to have postpartum hemorrhage (pph) related to uterine atony after her delivery.The crf noted that it was "unknown" if there was lower uterine segment (lus) bleeding involved in this event for the question asking about lus involvement.Prior to jada insertion, this subject received misoprostol and methergine (1 dose).The cumulative blood loss prior to the attempted jada insertion was noted as 844 ml.Jada treatment was initiated on (b)(6) 2021, 11 minutes after delivery of the placenta.The total in-dwelling time for jada was 3.28 hours and the total amount of blood collected in the canister during jada treatment was documented as 425 ml.The patient was treated with uterine artery embolization after the initial treatment with jada.The total blood loss for this case was 1569 ml.The patient received postpartum antibiotics (ancef) for "post uae." a note on the ruby crf stated, "jada inserted and bleeding continued.Jada removed and then replaced.Vaginal bleeding stopped but canister filling quickly.Decision to move to vir for uae" and "patient refused blood products." to the questions on the report asking, "did the patient experience a device or procedure related ae?" and "did the patient experience an sae, related or unrelated", the answers were checked "no".We requested if the site retained the device, recorded the lot number, and additional details for this case on 04/04/2022.This site discarded the device used in this case and do not record lot numbers for jada devices.A good faith effort was made to obtain this information.A jada device was inserted after uterotonics failed to stop pph.The patient's pph treatment continued to uae.As we are unable to rule out the use of jada in contributing to the need for the previous intervention, we are reporting this as a mdr in an abundance of caution.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
JADA SYSTEM
Type of Device
INTRAUTERINE VACUUM CONTRACTION SYSTEM
Manufacturer (Section D)
ALYDIA HEALTH
3495 edison way
menlo park CA 94025
Manufacturer (Section G)
ALYDIA HEALTH
3495 edison way
menlo park CA 94025
Manufacturer Contact
heather wisler
3495 edison way
menlo park, CA 94025
8445232666
MDR Report Key14251120
MDR Text Key290768498
Report Number3017425145-2022-00078
Device Sequence Number1
Product Code OQY
UDI-Device Identifier00850017882003
UDI-Public(01)00850017882003
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K201199
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 04/29/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberJADA - 1001
Device Catalogue NumberJADA-1001
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 04/01/2022
Initial Date FDA Received04/29/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age29 YR
Patient SexFemale
Patient Weight64 KG
Patient RaceWhite
-
-